Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hangjun Dai"'
Autor:
Huiqiang Huang, Rong Tao, Siguo Hao, Yu Yang, Hong Cen, Hui Zhou, Ye Guo, Liqun Zou, Junning Cao, Yunhong Huang, Jie Jin, Liling Zhang, Haiyan Yang, Xiaojing Xing, Huilai Zhang, Yanyan Liu, Kaiyang Ding, Qinzhou Qi, Xiaoli Zhu, Dan Zhu, Siyuan Wang, Teng Fang, Hangjun Dai, Qingmei Shi, Jason Yang
Publikováno v:
Journal of Clinical Oncology. 41:3032-3041
PURPOSE Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin lymphoma with limited treatment options. This phase II study evaluated the efficacy and safety of sugemalimab, an anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::188158472fac2e68ba7d38f227677482
https://doi.org/10.1200/jco.22.02367
https://doi.org/10.1200/jco.22.02367
Autor:
Jifang Gong, Junning Cao, Qingyuan Zhang, Nong Xu, Yanqiu Zhao, Baocai Xing, Zhanhui Miao, Yilong Wu, Hongming Pan, Quanli Gao, Xingya Li, Baorui Liu, Wei Li, Zhidong Pei, Hongqiang Xia, Qinzhou Qi, Hangjun Dai, Qingmei Shi, Jianxin Yang, Jin Li, Lin Shen
Publikováno v:
Cancer Immunology, Immunotherapy. 71:1897-1908
Background This first-in-human phase 1 trial is to evaluate the safety, pharmacokinetics, preliminary efficacy, and biomarkers of sugemalimab, a full-length, fully human anti-PD-L1 monoclonal antibody, in Chinese patients with advanced malignancies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3546384a1f6680ae0fb92dc78fcc294a
https://doi.org/10.1007/s00262-021-03102-3
https://doi.org/10.1007/s00262-021-03102-3
Autor:
Huiqiang Huang, Rong Tao, Yu Yang, Hong Cen, Hui Zhou, Ye Guo, Liqun Zou, Junning Cao, Yunhong Huang, Jie Jin, Liling Zhang, Haiyan Yang, Xiaojing Xing, Huilai Zhang, Yanyan Liu, Xiaoli Zhu, Teng Fang, Hangjun Dai, Qinzhou Qi, Jason Yang
Publikováno v:
Journal of Clinical Oncology. 40:7501-7501
7501 Background: R/R ENKTL is a rare and aggressive type of non-Hodgkin’s lymphoma. Responses to chemotherapy after failure of prior asparaginase-based regimen were not durable with a median OS of < 7 months (mos) and 1-year OS rate of < 20% (Lim e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ccaea53fcfb94652226367fa8718f39
https://doi.org/10.1200/jco.2022.40.16_suppl.7501
https://doi.org/10.1200/jco.2022.40.16_suppl.7501
Autor:
Lin Shen, Yi-Long Wu, Quanli Gao, Teddy Xia, Qingyuan Zhang, Zhanhui Miao, Hangjun Dai, Zhidong Pei, Rong Guo, Qing Zhou, Yanqiu Zhao, Nong Xu, Jianxin Yang, Jingru Wang
Publikováno v:
Journal of Clinical Oncology. 38:e21687-e21687
e21687 Background: Immuno-oncology (IO) monotherapy or combination with platinum-based chemo is the current standard of care for pts with PD-L1 expression ≥ 50% and EGFR, ALK, ROS1, BRAF negative advanced NSCLC in China. CS1001-101 phase Ib study i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::899092dc490762e136a54b2f40a80bc1
https://doi.org/10.1200/jco.2020.38.15_suppl.e21687
https://doi.org/10.1200/jco.2020.38.15_suppl.e21687
Autor:
Teng Fang, Liling Zhang, Ye Guo, Jianxin Yang, Dan Zhu, Hong Cen, Yu Yang, Haiyan Yang, Hui Zhou, Yunhong Huang, Hangjun Dai, Rong Tao, Huiqiang Huang, Liqun Zou, Wenbin Qian, Yueling Wang
Publikováno v:
Blood. 134:2833-2833
Background ENKTL is a subtype of mature T cell and NK cell lymphoma, with a higher incidence in Asia than in Europe and North America. Pts with rr-ENKTL have a poor prognosis after failing an L-asparaginase-based regimen, and lack effective treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10a889a6b83645a64a9eed0a631b82e3
https://doi.org/10.1182/blood-2019-121865
https://doi.org/10.1182/blood-2019-121865
Autor:
Junning Cao, Yan Zhang, Yin Wang, Jin Li, Lin Shen, Jingru Wang, Hongming Pan, Hangjun Dai, Nong Xu
Publikováno v:
Journal of Clinical Oncology. 37:2526-2526
2526 Background: CS1001 is the first full-length, fully human anti-PD-L1 mAb developed by the OMT transgenic rat platform, which mirrors natural IgG4 human antibody with expected PK profiles, and may potentially reduce the risk of immunogenicity and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f98f37d020e8790b8c5b9b754c9fb3a
https://doi.org/10.1200/jco.2019.37.15_suppl.2526
https://doi.org/10.1200/jco.2019.37.15_suppl.2526